Our Pipeline

Dragonfly's novel cytokines and TriNKET® NK cell engagers can both kill cancers and other disease targets directly, and improve the outcomes of other immunotherapy approaches like T-cell therapies.

Dragonfly’s pipeline is robust and continues to grow both internally and with BMS, Merck, AbbVie, and Gilead

Phase 3

Platform

Discovery

Preclinical

Phase 1

Phase 2

Dragonfly Internal

Phase 3

Platform

Discovery

Preclinical

Phase 1

Phase 2

BMS + Dragonfly Partnered

Phase 3

Platform

Discovery

Preclinical

Phase 1

Phase 2

Merck + Dragonfly Partnered

Phase 3

Platform

Discovery

Preclinical

Phase 1

Phase 2

AbbVie + Dragonfly Partnered

Phase 3

Platform

Discovery

Preclinical

Phase 1

Phase 2

Gilead + Dragonfly Partnered